Janux Therapeutics, Inc.

NasdaqGM:JANX 주식 보고서

시가총액: US$2.6b

Janux Therapeutics 관리

관리 기준 확인 4/4

Janux Therapeutics CEO는 David Campbell, Jun2017 에 임명되었습니다 의 임기는 7.42 년입니다. 총 연간 보상은 $ 4.19M, 14.9% 로 구성됩니다. 14.9% 급여 및 85.1% 보너스(회사 주식 및 옵션 포함). 는 $ 14.19M 가치에 해당하는 회사 주식의 0.54% 직접 소유합니다. 14.19M. 경영진과 이사회의 평균 재임 기간은 각각 2.3 년과 3.7 년입니다.

주요 정보

David Campbell

최고 경영자

US$4.2m

총 보상

CEO 급여 비율14.9%
CEO 임기7.4yrs
CEO 소유권0.5%
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간3.7yrs

최근 관리 업데이트

Recent updates

Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Oct 01
Janux Therapeutics (NASDAQ:JANX) Is In A Strong Position To Grow Its Business

Janux Therapeutics: Buoyed By Buyout Speculation

Sep 01

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Jul 01
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27

Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Feb 24
Companies Like Janux Therapeutics (NASDAQ:JANX) Are In A Position To Invest In Growth

Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Dec 29
Is Janux Therapeutics, Inc. (NASDAQ:JANX) Trading At A 37% Discount?

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Nov 04
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

Jul 20
We're Hopeful That Janux Therapeutics (NASDAQ:JANX) Will Use Its Cash Wisely

A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

May 23
A Look At The Intrinsic Value Of Janux Therapeutics, Inc. (NASDAQ:JANX)

Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Feb 09
Here's Why We're Not Too Worried About Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Oct 19
We Think Janux Therapeutics (NASDAQ:JANX) Can Afford To Drive Business Growth

Janux Therapeutics GAAP EPS of -$0.41, revenue of $2.37M

Aug 09

We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Jun 05
We Think Janux Therapeutics (NASDAQ:JANX) Can Easily Afford To Drive Business Growth

Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Feb 19
Janux Therapeutics (NASDAQ:JANX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

Nov 03
Here's Why We're Not At All Concerned With Janux Therapeutics' (NASDAQ:JANX) Cash Burn Situation

CEO 보상 분석

David Campbell 의 보수는 Janux Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$44m

Mar 31 2024n/an/a

-US$56m

Dec 31 2023US$4mUS$625k

-US$58m

Sep 30 2023n/an/a

-US$63m

Jun 30 2023n/an/a

-US$68m

Mar 31 2023n/an/a

-US$67m

Dec 31 2022US$6mUS$550k

-US$63m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$54m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$8mUS$459k

-US$33m

Sep 30 2021n/an/a

-US$21m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$812kUS$405k

-US$7m

보상 대 시장: David 의 총 보상 ($USD 4.19M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 6.60M ).

보상과 수익: David 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.


CEO

David Campbell (64 yo)

7.4yrs

테뉴어

US$4,193,269

보상

Dr. David Campbell, Ph D serves as President, Chief Executive Officer and Director of Janux Therapeutics, Inc. since inception in June 2017. He founded Janux in 2017 to develop tumor-specific cancer therap...


리더십 팀

이름위치테뉴어보상소유권
David Campbell
President7.4yrsUS$4.19m0.54%
$ 14.2m
Charles Winter
Chief Technical Officer1.8yrsUS$1.61m0.098%
$ 2.6m
Byron Robinson
Chief Strategy Officer2.8yrsUS$1.74m0%
$ 0
Matt Whitmire
Vice President of Financeless than a year데이터 없음데이터 없음
Maria Dobek
Principal Accounting Officer & VP of Accountingless than a year데이터 없음데이터 없음
Tommy Diraimondo
Chief Scientific Officerless than a year데이터 없음0.19%
$ 4.9m
James Pennington
General Counsel3.3yrs데이터 없음데이터 없음
Andy Meyer
Chief Business Officer3.7yrs데이터 없음0.13%
$ 3.4m

2.3yrs

평균 재임 기간

47.5yo

평균 연령

경험이 풍부한 관리: JANX 의 관리팀은 경험 ( 2.3 년 평균 재직 기간)으로 간주됩니다.


이사회 구성원

이름위치테뉴어보상소유권
David Campbell
President7.4yrsUS$4.19m0.54%
$ 14.2m
Charles Hart
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Vickie Capps
Independent Director3.7yrsUS$173.01k0.13%
$ 3.4m
Ronald Barrett
Chairperson3.2yrsUS$162.69k0%
$ 0
Mark Davis
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Alana McNulty
Independent Director3.2yrsUS$166.57k0%
$ 0
Charles Craik
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Sheila Gujrathi
Director3.7yrsUS$158.01k0.21%
$ 5.7m
Winston Kung
Independent Director2.2yrsUS$164.77k0%
$ 0
Jake Simson
Independent Director3.7yrsUS$172.07k0%
$ 0
Greg Weiss
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Jennifer Maynard
Member of Scientific Advisory Boardno data데이터 없음데이터 없음

3.7yrs

평균 재임 기간

61yo

평균 연령

경험이 풍부한 이사회: JANX 의 이사회경험(평균 재직 기간 3.7 년)으로 간주됩니다.